Drug Profile
Research programme: liposomal anticancer radiotherapies - Algeta
Alternative Names: RV-1 programmeLatest Information Update: 11 Mar 2014
Price :
$50
*
At a glance
- Originator Algeta
- Class Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Gynaecological cancer
Most Recent Events
- 06 Mar 2014 Algeta has been acquired by Bayer
- 24 Feb 2009 Suspended - Preclinical for Gynaecological cancer in Norway (unspecified route)
- 29 Nov 2006 Preclinical development is ongoing